Find Resources
Best Practices that show evidence of effectiveness in improving public health outcomes when implemented in multiple real-life settings, as indicated by achievement of aims consistent with the objectives of the activities.
RELEASE DATE:
Peer Review Study, Summary Report/Recommendations
The guidance outlined in this report provides a roadmap for the ethical inclusion of pregnant women’s experiences in in the development and deployment of vaccines against emerging viruses. Recommendations include bolstering health information surveillance systems, stakeholder engagement with health care, women, families and communities, and changing the narrative about pregnancy and clinical research efforts. Recommendations require commitment of financial resources, addressing inequities in public health and whenever possible, the inclusion of perspectives of pregnant women. Lastly, the authors recommend that “When there is a limited supply of vaccine against a pathogenic threat that disproportionately affects pregnant women, their offspring, or both, or when only one vaccine among several is appropriate for use in pregnancy, then pregnant women should be among the priority groups to be offered the vaccine.” This prioritization process is key to addressing inequities and are guidance for future pandemic response efforts.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
Maternity healthcare professionals (MHCPs) play an important role in promoting vaccines and influencing the perspectives of pregnant women. This systematic review outlines the views and experiences of these key workforce members involved in the provision of the maternal influenza vaccine worldwide. In order to promote vaccine uptake, results indicate that it is important to educate MHCPs, ensure there is sufficient time for discussions, and implement electronic vaccination prompts. These, in addition to national policies and guidelines, helped increase the confidence of these professionals in recommending vaccination.
Best Practices that show evidence of effectiveness in improving public health outcomes when implemented in multiple real-life settings, as indicated by achievement of aims consistent with the objectives of the activities.
RELEASE DATE:
Peer Review Study
The guidance outlined in this report provides a roadmap for the ethical inclusion of pregnant women’s experiences in the development and deployment of vaccines against emerging viruses. Recommendations include (1) bolstering health information surveillance systems, (2) stakeholder engagement with health care, women, families and communities, and (3) changing the narrative about pregnancy and clinical research efforts. Recommendations require commitment of financial resources, addressing inequities in public health, and whenever possible, the inclusion of perspectives of pregnant women. Lastly, the authors recommend that “When there is a limited supply of vaccine against a pathogenic threat that disproportionately affects pregnant women, their offspring, or both, or when only one vaccine among several is appropriate for use in pregnancy, then pregnant women should be among the priority groups to be offered the vaccine.” This prioritization process is key to addressing inequities and are guidance for future pandemic response efforts.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This study describes harm reduction and health services provided by the U.S. syringe services programs (SSPs) in 2019 and changes in provision of those services in 2020. Many SSPs that offered health services in 2019 and remained operational in 2020 increased telehealth provision of mental health and primary care services, increased MOUD provision, and expanded harm reduction services, but most SSPs reduced or stopped on-site HIV and HCV testing. With the record high opioid overdose fatality rates in 2020, sustaining the trajectory of SSP growth and innovation leading up to and through 2020 requires ensuring adequate and flexible funding to support the life-saving work of SSPs in preventing future overdose deaths and outbreaks of HIV and HCV.
Novel Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and are in the process of generating evidence of effectiveness or may not yet be tested.
RELEASE DATE:
Peer Review Study
Survey on the impact of COVID-19 on pregnant women that can be adapted to assessing the experiences of this population in future crises. This article discusses the findings of a survey distributed to 1,439 Dutch women who were pregnant between April 4-May 10, 2020. The survey included multiple scales, such as the COVID-19 and Perinatal Experiences scale, the State-Trait Anxiety Inventory, and the Edinburgh Depression Scale, and compared results with a similar survey completed in 2018. The survey included 8 key domain areas, including topics like financial stress, social support, partner support, anxiety symptoms, and depressive symptoms, to name a few. Women reported higher worries related to COVID-19 in general, and also reported higher work/financial related worries. Depression and anxiety also increased, with anxiety rates increasing two-fold.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
This article describes the implementation of a medical student-run, free virtual clinic providing medication assisted treatment (MAT) for opioid use disorder (OUD) in Miami, Florida during the COVID-19 pandemic. Eligibility criteria for accessing services through the clinic included Florida residency and an income below 200% of the federal poverty level. The article describes how the students promoted the clinic, the process for providing MAT virtually (under supervision of an attending physician), patient characteristics, and reports process evaluation data for the clinic. The practice strategy this article is focused on is access to MAT for people with OUD during the COVID-19 pandemic.
Promising Practices that show evidence of effectiveness in improving public health outcomes in a specific real-life setting, as indicated by achievement of aims consistent with the objectives of the activities, and are suitable for adaptation by other communities.
RELEASE DATE:
Peer Review Study
This article presents results from an intervention to provide medication assisted treatment (MAT) to individuals with opioid use disorder via telemedicine. This article describes outcomes for patients enrolled in the NYC Health+Hospitals Virtual Buprenorphine Clinic during the first nine weeks of the COVID-19 pandemic (March 26, 2020 through May 28, 2020). Results from this evaluation were mixed. Loss-to-follow-up was similar to rates observed in studies of in-person opioid treatment, but the authors note telemedicine-based opioid treatment poses barriers to patients who frequently change mobile phones or phone numbers, and patients with unreliable internet access. The authors also note that the generalizability of this intervention may be limited in settings with different patient populations or staff capacity.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This article evaluates a partnership between the University of Maryland, Baltimore – an urban academic treatment center – and multiple rural behavioral health treatment centers to provide medication assisted treatment (MAT) to individuals with opioid use disorder via videoconference. Retention rates and toxicology results for patients who received MAT via videoconference were comparable to those receiving face-to-face treatment. It should be noted that data for this study were collected prior to the onset of the COVID-19 pandemic.
Emerging Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and produce early results that are consistent with the objectives of the activities and thus indicate effectiveness.
RELEASE DATE:
Peer Review Study
This article presents the results of a non-randomized cohort study comparing opioid agonist therapy (medication assisted treatment [MAT]) for opioid use disorder received via telemedicine, in-person, or a mix of telemedicine and in-person visits. The study was conducted between January 2011 and June 2012 in Ontario, Canada. The telemedicine group had the highest one-year treatment retention rate, followed by the mixed group, and the in-person group had the lowest one-year treatment retention rate. The results suggest telemedicine could be an effective means of increasing access to MAT for opioid use disorder. It should be noted that the study was conducted prior to the COVID-19 pandemic, and replicability will vary based on local resources and MAT regulations.
Novel Practices that show potential to achieve desirable public health outcomes in a specific real-life setting and are in the process of generating evidence of effectiveness or may not yet be tested.
RELEASE DATE:
Peer Review Study
Based on a literature review, the article synthesizes strategies used to prevent interruption of care for persons with opioid use disorders (SUDs). The review included OUD treatment and harm reduction services in five continents and a range of settings from substance use treatment to street outreach programs. Innovative service modifications to adapt to COVID-19 circumstances primarily involved expanded use of telehealth services (e.g., telemedicine visits for buprenorphine, virtual individual or group therapy sessions, provision of donated or publicly available phones), increased take-home medication allowances for methadone and buprenorphine, expanded uptake of long-acting opioid medications (e.g. extended-release buprenorphine and naltrexone), home delivery of services (e.g. MOUD, naloxone and urine drug screening), outreach and makeshift services for delivering MOUD and naloxone, and provision of a safe supply of opioids.